Physico-chemical and Biopharmaceutical Investigations of Novel Drug Delivery Systems for Oral Administration of Lipophilic Drugs

用于口服亲脂性药物的新型给药系统的理化和生物制药研究

• 批准号: DP0558920
• 负责人: Prof Clive Prestidge
• 金额: $ 18.02万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-04-05 至 2008-05-01
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0558920
• 关键词: Physico; chemical; Biopharmaceutical; Investigations; Novel; Physico; chemical; Biopharmaceutical; Investigations; Novel

The new platform technology for carrying lipophilic molecules will be applicable to many molecules currently under development by Australian Industry and will inspire novel encapsulation approaches to new and existing drugs as well as functional foods and nutraceuticals. Improved oral bioavailability of anticancer drugs will improve the quality of life of patients, reduce health care costs and provide broader benefits to the community. The Australian biotechnology/pharmaceutical industries can share in a greater proportion of the US$50 billion market for specialised drug delivery, which is increasing by 20% annually. Australia's scientific competitiveness will be strengthened in the fields of nano-encapsulation and colloidal delivery.

携带亲脂分子的新平台技术将适用于澳大利亚工业目前正在开发的许多分子，并将激发新的和现有药物的新型封装方法以及功能性食品和营养。改善抗癌药物的口服生物利用度将改善患者的生活质量，降低医疗保健成本并为社区带来更大的收益。澳大利亚生物技术/制药行业可以在500亿美元的专用药物交付市场中共享更大的比例，该市场每年增加20％。澳大利亚的科学竞争力将在纳米封装和胶体交付领域得到增强。